Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2007 Jan 22;150(2):248. doi: 10.1038/sj.bjp.0707129

Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates

S K Kelley, T Gelzleichter, D Xie, W P Lee, W C Darbonne, F Qureshi, K Kissler, E Oflazoglu, I S Grewal
PMCID: PMC2042909

Correction to: British Journal of Pharmacology (2006) 148, 1116–1123. doi:10.1038/sj.bjp.0706828

Since the above publication, the authors have noticed an error in the x axis of Figure 4, the labeling should read μl−1. The correct figure and legend is shown below:

Figure 4.

Figure 4

Pharmacodynamic response of lymphocyte and mono-nuclear cell counts to SGN-40 either in cynomolgus monkeys. Blood was analyzed by FACS. Lymphocytes were identified using monoclonal antibody markers recognizing surface-cell CD45 and CD14. Total peripheral blood lymphocytes were identified as CD45+/CD14 cells within the light-scatter gate. (a) Effect of SGN-40 on B-lymphocytes as characterized using monoclonal antibodies to CD20 cell-surface marker. (b) Pharmacodynamic response of CD3+/CD4+ lymphocyte counts to SGN-40 in cynomolgus monkeys. Lymphocyte phenotypes were characterized using monoclonal antibodies to CD3 and CD4 cell-surface markers. (c) Pharmacodynamic response of CD3+/CD8+ lymphocyte counts to SGN-40 in cynomolgus monkeys. Lymphocyte phenotypes were further characterized using monoclonal antibodies to CD3 and CD8 cell-surface markers. Data represent mean values (±s.d.).

The authors would like to apologise for this mistake.


Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES